Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit | 1 | GlobeNewswire (USA) | ||
05.03. | Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program | 1 | GlobeNewswire (USA) | ||
04.03. | Passage Bio files for $200M mixed shelf offering | 1 | Seeking Alpha | ||
04.03. | Passage Bio GAAP EPS of -$1.86 beats by $0.04 | 1 | Seeking Alpha | ||
04.03. | Passage BIO, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
04.03. | Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights | 78 | GlobeNewswire (Europe) | Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven... ► Artikel lesen | |
29.02. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.02. | Passage Bio to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
31.01. | Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | 1 | GlobeNewswire (USA) | ||
05.01. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.12.23 | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.12.23 | Passage Bio stock climbs 9% on dementia study, program update | 1 | Seeking Alpha | ||
20.12.23 | Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities | 2 | Benzinga.com | ||
20.12.23 | US STOCKS Passage Bio, Discover Financial, Alphabet | 5 | Reuters | ||
20.12.23 | Passage Bio Announces Initial Clinical Data From Phase 1/2 UpliFT-D Trial On PBFT02 | 1 | RTTNews | ||
20.12.23 | Passage Bio rises on positive early-stage data for dementia treatment | 1 | Reuters | ||
20.12.23 | Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities | 343 | GlobeNewswire (Europe) | Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months... ► Artikel lesen | |
20.12.23 | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.11.23 | Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) | 254 | GlobeNewswire (Europe) | PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system... ► Artikel lesen | |
13.11.23 | Passage Bio GAAP EPS of -$0.49 misses by $0.03 | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,160 | -4,98 % | Allianz, Evotec, Nel ASA, Nordex, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
CORE ONE LABS | 0,134 | -5,30 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
MAINZ BIOMED | 0,790 | -5,05 % | EQS-News: Mainz BioMed N.V.: Positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger mRNA-Biomarker und des firmeneigenen KI-Algorithmus zur Integration in die klinische FDA-Zulassungsstudie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed: Positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger mRNA-Biomarker... ► Artikel lesen | |
TREVENA | 0,378 | +5,74 % | TREVENA INC - 8-K, Current Report | ||
DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
BLUEBIRD BIO | 0,843 | -2,41 % | bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the... ► Artikel lesen | |
GALAPAGOS NV | 26,500 | -1,41 % | Galapagos NV: Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 | Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Mechelen... ► Artikel lesen | |
GINKGO BIOWORKS | 0,780 | 0,00 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
CELLECTAR BIOSCIENCES | 2,860 | 0,00 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 0,950 | +5,56 % | Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting | ||
COHERUS | 1,824 | -3,65 % | Coherus BioSciences, Inc.: Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
CHIMERIX | 0,828 | -2,01 % | Chimerix, Inc.: Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 | ||
BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
ONCOLYTICS BIOTECH | 1,030 | +4,04 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen |